2.09
-0.01(-0.48%)
Currency In USD
| Previous Close | 2.1 |
| Open | 2.09 |
| Day High | 2.09 |
| Day Low | 2.09 |
| 52-Week High | 2.17 |
| 52-Week Low | 1.34 |
| Volume | 2.8M |
| Average Volume | 718,706 |
| Market Cap | 104.76M |
| PE | -1.45 |
| EPS | -1.44 |
| Moving Average 50 Days | 2.09 |
| Moving Average 200 Days | 1.92 |
| Change | -0.01 |
If you invested $1000 in HilleVax, Inc. (HLVX) since IPO date, it would be worth $109.48 as of September 29, 2025 at a share price of $2.09. Whereas If you bought $1000 worth of HilleVax, Inc. (HLVX) shares 2 years ago, it would be worth $155.39 as of September 29, 2025 at a share price of $2.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
HilleVax Reports Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Aug 06, 2025 8:05 PM GMT
BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2025. Seco
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
GlobeNewswire Inc.
Aug 04, 2025 11:00 AM GMT
BOSTON, Mass., and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced today they have entered into a definitive me
HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
GlobeNewswire Inc.
May 08, 2025 11:00 AM GMT
$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business development related activities a
Data not available